Lipids from methanotrophic bacteria for cholesterol reduction
The present invention provides the use of lipids from methanotrophic bacteria for the manufacture of a composition for oral administration for use in the treatment of animal subjects to reduce plasma cholesterol levels therein or to reduce the ratio of LDL to HDL cholesterol in the plasma thereof. The composition is also useful for increasing plasma docosahexaenoic acid and as immuno-protectant.
1 - 17 . (canceled)
18 . A method for reducing plasma cholesterol of an animal or maintaining a reduced cholesterol level in an animal or reducing LDL:HDL cholesterol ratio in plasma of an animal comprising orally administering to an animal in need thereof, an oral dosage composition comprising an effective amount of microbial lipids.
19 . A method for increasing plasma docosahexanenoic acid (DHA) in an animal comprising orally administering to an animal in need thereof, an oral dosage composition comprising microbial lipids.
20 . A method for achieving an immuno-protectant effect in an animal comprising orally administering to an animal in need thereof, an oral dosage composition comprising microbial lipids.
21 . The method as claimed in claim 18 , wherein said animal is a human.
22 . The method as claimed in claim 19 , wherein said animal is a human.
23 . The method as claimed in claim 20 , wherein said animal is a human.
24 . The method as claimed claim 18 , wherein said animal is a fish.
25 . The method as claimed claim 19 , wherein said animal is a fish.
26 . The method as claimed claim 20 , wherein said animal is a fish.
27 . The method as claimed in claim 24 , wherein said fish is a juvenile fish.
28 . The method as claimed in claim 25 , wherein said fish is a juvenile fish.
29 . The method as claimed in claim 26 , wherein said fish is a juvenile fish.
30 . The method as claimed in claim 18 , wherein said microbial lipids are methanotrophic bacterial lipids.
31 . The method as claimed in claim 19 , wherein said microbial lipids are methanotrophic bacterial lipids.
32 . The method as claimed in claim 20 , wherein said microbial lipids are methanotrophic bacterial lipids.
33 . The method as claimed in claim 18 , wherein said composition is an encapsulated composition.
34 . The method as claimed in claim 19 , wherein said composition is an encapsulated composition.
35 . The method as claimed in claim 20 , wherein said composition is an encapsulated composition.
36 . A composition comprising at least 80% wt. microbial lipid, and comprising at least 10 g of said microbial lipid.
37 . The composition as claimed in claim 36 , wherein said lipid is phosphatidylethanolamine.
38 . The composition as claimed in claim 37 , wherein said phosphatidylethanolamine is a phosphatidylethanolamine having C 16:0 and/or C 16:1 fatty acid side chains.
39 . A foodstuff comprising a microbial lipid extract and a nutrient component.
40 . The foodstuff as claimed in claim 39 , wherein said nutrient component is of non-microbial origin.
41 . A pharmaceutical or nutraceutical composition comprising a microbial lipid extract together with a pharmaceutically acceptable carrier or excipient.
42 . A food product harvested from an animal fed with a microbial lipid.
43 . The food product as claimed in claim 42 , wherein said food product is an avian egg.